Holen Sie sich die Stockscreener-App
3.34
7.73%
-0.28
Handel nachbörslich:
3.43
0.09
+2.69%
Schlusskurs vom Vortag:
$3.62
Offen:
$3.42
24-Stunden-Volumen:
3.26M
Relative Volume:
2.25
Marktkapitalisierung:
$321.44M
Einnahmen:
$20.65M
Nettoeinkommen (Verlust:
$-192.65M
KGV:
-1.2896
EPS:
-2.59
Netto-Cashflow:
$-134.39M
1W Leistung:
-26.91%
1M Leistung:
-50.22%
6M Leistung:
-30.27%
1J Leistung:
-60.80%
1-Tages-Spanne:
$3.095
$3.63
1-Wochen-Bereich:
$3.095
$4.56
52-Wochen-Spanne:
$3.095
$9.305
Verve Therapeutics Inc Stock (VERV) Company Profile
Firmenname
Verve Therapeutics Inc
Sektor
Branche
Telefon
(978) 501-3026
Adresse
201 BROOKLINE AVENUE, BOSTON
Vergleichen Sie VERV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
3.34 | 321.44M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-10-06 | Eingeleitet | Credit Suisse | Neutral |
| 2022-08-25 | Hochstufung | Stifel | Hold → Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-07-12 | Eingeleitet | Guggenheim | Buy |
| 2021-07-12 | Eingeleitet | JP Morgan | Neutral |
| 2021-07-12 | Eingeleitet | Jefferies | Buy |
| 2021-07-12 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Verve Therapeutics Inc Aktie (VERV) Neueste Nachrichten
Verve Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics, Inc. LawsuitVERV - ACCESS Newswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Verve Therapeutics Strengthens Team with Strategic Equity Awards Worth $232K - Stock Titan
Verve Therapeutics CEO Sekar sells $40,761 in stock By Investing.com - Investing.com South Africa
Verve therapeutics CAO Joan Nickerson sells $11,524 in stock - Investing.com India
Verve Therapeutics CEO Sekar sells $40,761 in stock - Investing.com India
Verve Therapeutics Executives Sell Shares - TradingView
Verve therapeutics CAO Joan Nickerson sells $11,524 in stock By Investing.com - Investing.com UK
Is Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy? - Insider Monkey
Class Action Filed Against Verve Therapeutics, Inc. (VERV)October 28, 2024 Deadline to Join – Contact Levi & Korsinsky - ACCESS Newswire
Swiss National Bank Purchases 18,000 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Did Verve Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate– VERV - ACCESS Newswire
Investigation announced for Long-Term Investors in shares - openPR.com
Pixalate Releases Q4 2024 United Kingdom Connected TV (CTV) Ad Supply Chain Trends Report: Samsung Smart TV Leads in Device Market Share (30%); Ad Fraud (IVT) Rate Hits 16% - GlobeNewswire Inc.
Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts - Seeking Alpha
Verve Therapeutics gets FDA approval to begin cholesterol treatment trial - MSN
Verve Therapeutics Announces Clearance of Investigational - GlobeNewswire
Verve Therapeutics Says US FDA Clears Verve-102 IND Application for Premature Coronary Artery Disease - MarketScreener
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose - The Manila Times
Game-Changing FDA Green Light: Verve's One-Time Gene Therapy Takes On High Cholesterol - Stock Titan
Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Bought by Arizona State Retirement System - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Bought by US Bancorp DE - Defense World
Verve Therapeutics Inc (VERV): Significant Improvements, Worth Considering - Stocks Register
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by Rhumbline Advisers - Defense World
IFP Advisors Inc Boosts Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
(VERV) Technical Data - news.stocktradersdaily.com
Verve Therapeutics (NASDAQ:VERV) Shares Gap Down After Analyst Downgrade - Defense World
Verve Therapeutics (NASDAQ:VERV) Price Target Cut to $15.00 by Analysts at Royal Bank of Canada - Defense World
Verve Therapeutics price target lowered to $15 from $17 at RBC Capital - TipRanks
RBC Cuts Price Target on Verve Therapeutics to $15 From $17, Keeps Outperform, Speculative Risk - Marketscreener.com
How Verve Therapeutics Is Attracting Talent: New Equity Compensation Package Details - StockTitan
Analysts Set Expectations for VERV Q1 Earnings - Defense World
Verve Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - ACCESS Newswire
HC Wainwright Forecasts Strong Price Appreciation for Verve Therapeutics (NASDAQ:VERV) Stock - Defense World
Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - ACCESS Newswire
Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates - MSN
H.C. Wainwright lifts VERVE Therapeutics price target to $15 By Investing.com - Investing.com Canada
Promising Progress and Strategic Partnerships Position Verve Therapeutics as a Compelling Buy Opportunity - TipRanks
Verve Can Shrug Off Vertex Loss But Lilly Opt-In Is Crucial - News & Insights
Verve TherapeuticsKey Data Catalysts, Major Share Price Volatility In Play In Q2 - Seeking Alpha
Buy Rating for Verve Therapeutics: Promising Program Progress and Strong Financial Position - TipRanks
Verve Therapeutics: Buy Rating Backed by Promising VERVE-102 Program and Strategic Catalysts - TipRanks
VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Verve Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance UK
Verve Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Verve Therapeutics: Q4 Earnings Snapshot - Houston Chronicle
Verve Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Finanzdaten der Verve Therapeutics Inc-Aktie (VERV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):